Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Identifieur interne : 002621 ( Ncbi/Curation ); précédent : 002620; suivant : 002622Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Auteurs : Iracema Leroi [Royaume-Uni] ; Ross Overshott ; E Jane Byrne ; Emily Daniel ; Alistair BurnsSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Dementia (complications), Dementia (drug therapy), Double-Blind Method, Drug Evaluation, Excitatory Amino Acid Antagonists (therapeutic use), Female, Humans, Male, Memantine (therapeutic use), Mental Status Schedule, Parkinson Disease (complications), Parkinson Disease (drug therapy), Severity of Illness Index, Time Factors, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Excitatory Amino Acid Antagonists, Memantine.
- complications : Dementia, Parkinson Disease.
- drug therapy : Dementia, Parkinson Disease.
- Aged, Aged, 80 and over, Double-Blind Method, Drug Evaluation, Female, Humans, Male, Mental Status Schedule, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD.
DOI: 10.1002/mds.22495
PubMed: 19370737
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D56
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001D56
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C07
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002621
Links to Exploration step
pubmed:19370737Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized controlled trial of memantine in dementia associated with Parkinson's disease.</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name><affiliation wicri:level="1"><nlm:affiliation>Lancashire Care Trust, Royal Blackburn Hospital, Blackburn, United Kingdom. ileroi2002@yahoo.co.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Lancashire Care Trust, Royal Blackburn Hospital, Blackburn</wicri:regionArea><wicri:noRegion>Blackburn</wicri:noRegion></affiliation></author><author><name sortKey="Overshott, Ross" sort="Overshott, Ross" uniqKey="Overshott R" first="Ross" last="Overshott">Ross Overshott</name></author><author><name sortKey="Byrne, E Jane" sort="Byrne, E Jane" uniqKey="Byrne E" first="E Jane" last="Byrne">E Jane Byrne</name></author><author><name sortKey="Daniel, Emily" sort="Daniel, Emily" uniqKey="Daniel E" first="Emily" last="Daniel">Emily Daniel</name></author><author><name sortKey="Burns, Alistair" sort="Burns, Alistair" uniqKey="Burns A" first="Alistair" last="Burns">Alistair Burns</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22495</idno><idno type="RBID">pubmed:19370737</idno><idno type="pmid">19370737</idno><idno type="wicri:Area/PubMed/Corpus">001D56</idno><idno type="wicri:Area/PubMed/Curation">001D56</idno><idno type="wicri:Area/PubMed/Checkpoint">001C07</idno><idno type="wicri:Area/Ncbi/Merge">002621</idno><idno type="wicri:Area/Ncbi/Curation">002621</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized controlled trial of memantine in dementia associated with Parkinson's disease.</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name><affiliation wicri:level="1"><nlm:affiliation>Lancashire Care Trust, Royal Blackburn Hospital, Blackburn, United Kingdom. ileroi2002@yahoo.co.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Lancashire Care Trust, Royal Blackburn Hospital, Blackburn</wicri:regionArea><wicri:noRegion>Blackburn</wicri:noRegion></affiliation></author><author><name sortKey="Overshott, Ross" sort="Overshott, Ross" uniqKey="Overshott R" first="Ross" last="Overshott">Ross Overshott</name></author><author><name sortKey="Byrne, E Jane" sort="Byrne, E Jane" uniqKey="Byrne E" first="E Jane" last="Byrne">E Jane Byrne</name></author><author><name sortKey="Daniel, Emily" sort="Daniel, Emily" uniqKey="Daniel E" first="Emily" last="Daniel">Emily Daniel</name></author><author><name sortKey="Burns, Alistair" sort="Burns, Alistair" uniqKey="Burns A" first="Alistair" last="Burns">Alistair Burns</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Dementia (complications)</term><term>Dementia (drug therapy)</term><term>Double-Blind Method</term><term>Drug Evaluation</term><term>Excitatory Amino Acid Antagonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Memantine (therapeutic use)</term><term>Mental Status Schedule</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term><term>Memantine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Mental Status Schedule</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002621 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002621 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:19370737
|texte= Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:19370737" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |